HRMY - Rasio kapitalisasi pasar marang pendapatan Harmony Biosciences Inc
Harmony Biosciences maintains the status of an authoritative brand in the therapy of rare neurological pathologies. The GURU.Markets terminal provides a price/sales multiple chart for the company, where the value has settled at 2.00. The business relies on a closed-loop support system for patients with sleep disorders, however, dependence on a single product and challenges in expanding FDA indications are hindering expansion into new markets.
Rincian metrik lan analitis perusahaan harmonybiosciences.com (HRMY)
- kuotasi saiki lan rata-rata prakiraan nilai:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Utang marang Modal Harmony Biosciences|HRMY - Utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal Harmony Biosciences|HRMY - Gunggung utang perusahaan|Utang marang nilai buku Harmony Corp|HRMY - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Harmony Biosciences|Likuiditas darurat harmonybiosciences.com
- rincian asil keuangan lan kelipatan valuasi:
HRMY - Bathi resik perusahaan|Prakiraan bathi resik Harmony Biosciences|HRMY - Pangali P/E|Prakiraan rega marang bathi Harmony Pharma|HRMY - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Harmony Biosciences|HRMY - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Harmony Biosciences|HRMY - Bathi resik saben saham (EPS TTM)|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan harmonybiosciences.com|HRMY - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Harmony Biosciences
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:HRMY (Harmony Biosciences Holdings, Inc.)
The price-to-sales ratio measures the market value of a business per unit of generated revenue, allowing for an assessment of whether assets are overpaid relative to their operational efficiency. For Harmony Biosciences (HRMY), which depends on insurance reimbursements for narcolepsy medications, fluctuations in the P/S ratio reflect market confidence in the sustainability of cash flows, cautioning investors against purchasing an overvalued asset.
Perusahaan pesaing
BIIB (Biogen) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NBIX (Neurocrine Corp)|Regencell Bioscience - Rasio rega marang pendapatan|Axsome Therapeutics - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Rasio rega marang pendapatan|Rega marang dodolan Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - Multiplikator P/S|CPRX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S DNLI|Biohaven - Rasio kapitalisasi marang pendapatan|Multiplikator P/S AMLX (amylyx.com)|Trevi Pharma (TRVI) - Rega marang dodolan|Praxis Corp - Multiplikator P/S|Anavex Corp (AVXL) - Kapitalisasi marang pendapatan|CBLL: Multiplikator P/S|Prothena Biosciences - Rasio kapitalisasi pasar marang pendapatan|ALEC (alector.com) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANNX (Annexon Biosciences)|Rasio rega marang pendapatan Omeros Corporation (OMER)|Neurogene Corp - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan AC Immune S.A. ACIU|Koefisien rega marang pendapatan Voyager Therapeutics (VYGR)|Neumora - Multiplikator P/S|Rasio rega marang dodolan SCLX|Tevogen Bio Inc. (TVGN) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan ACOG|CGTX (cogrx.com) - Multiplikator P/S|Kapitalisasi marang pendapatan inhibikase.com (IKT)|Rasio rega marang pendapatan Cassava Sciences Inc (SAVA)|Koefisien rega marang pendapatan Assertio|Multiplikator P/S COYA (Coya Therapeutics, Inc.)|Kapitalisasi marang volume dodolan VTGN (VistaGen Therapeutics Inc)|OVID: Kapitalisasi marang pendapatan|ABOS: Rasio rega marang pendapatan|CervoMed (CRVO) - Rasio rega marang pendapatan|Rega marang dodolan Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan PEPG (PepGen)|Kapitalisasi marang pendapatan JUNS (Jupiter Neurosciences, Inc.)|Multiplikator P/S relmada.com (RLMD)|Rasio rega marang pendapatan Annovis Bio Corp ANVS|GRCE: Rasio kapitalisasi marang pendapatan|AIFF - Rasio rega marang pendapatan|KLTO (anewmeds.com) - Rasio kapitalisasi marang pendapatan|NRSN (NeuroSense Therapeutics Ltd.) - Kapitalisasi marang pendapatan|revivapharma.com - Rasio kapitalisasi pasar marang pendapatan|MTVA (metaviatx.com) - Multiplikator P/S|NRXS: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HSDT|PASG - Rega marang dodolan|Multiplikator P/S NEUP (Neuphoria Therapeutics)|NERV: Rasio kapitalisasi marang pendapatan|ATHA: Kapitalisasi marang pendapatan|Addex Therapeutics Ltd - Kapitalisasi marang volume dodolan|Alzamend Neuro, Inc. (ALZN) - Rasio rega marang pendapatan|CYCN (Cyclerion Therapeutics Inc.) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan PTIX|KTTA: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Brainstorm Cell Therapeutics, Inc. BCLI|Rasio kapitalisasi pasar marang pendapatan CARA|chromocell.com - Multiplikator P/S|Rasio rega marang dodolan ELYM|ITCI: Multiplikator P/S|Rega marang dodolan Longboard Pharmaceuticals, Inc. (LBPH)|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|NKGN: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NRBO|SAGE: Rasio rega marang dodolan|Synaptogenix Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - Multiplikator P/S|Anew Medical (WENA) - Kapitalisasi marang pendapatan|CERE (Cerevel Corp) - Kapitalisasi marang pendapatan
